Physician profile
Beth M Leventhal
NPI 1265468797
$4,288.46
in general payments reported to CMS, 2019-2025
20 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $75.58 · 2021: $342 · 2022: $209 · 2023: $354 · 2024: $2,371 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,158.58 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $291.90 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $259.02 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $226.19 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.85 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $194.53 | 2021-2024 | Jesduvroq, Benlysta |
| Amgen INC. | $125.10 | 2019-2021 | |
| Horizon Therapeutics Plc | $113.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.97 | 2025 | |
| Aurinia Pharma U.S., INC. | $63.90 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $63.30 | 2019-2025 | Rayaldee |
| Boston Scientific Corporation | $60.89 | 2019 | |
| Akebia Therapeutics INC | $54.83 | 2019-2025 | Vafseo |
| Novo Nordisk INC | $43.62 | 2025 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $39.92 | 2019 | |
| Vifor Pharma, INC. | $35.53 | 2020-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $27.06 | 2019-2020 | |
| Ardelyx, INC. | $24.00 | 2024 | Ibsrela |
| Avion Pharmaceuticals | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.